| Revenue growth | 16.6% YoY in Q4; 12.2% for FY26. |
|---|---|
| Margins | Normalized FY26 EBITDA margin stable at 28.3%. |
| Demand visibility | High; driven by aging population and chronic disease prevalence. |
| Management confidence | Strong; emphasizing resilience of business model and digital scale-up. |
Growth
Q4 revenue grew 16.6%; FY26 revenue up 12.2% to ₹2,763 cr. FY26 PAT rose 3.6% to ₹510 cr.
Outlook
Focus on AI-powered 'Sovaaka' wellness brand, digital transformation, and expanding infrastructure in South and West India.
Risks
Impact of new labour code (₹30 cr) and intense market fragmentation from standalone and hospital labs.
Earnings Call filed with NSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,952.30
- Market cap
- ₹32,769 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 60.5×Sector 57.8×
- Promoter holding
- 53.19%-0.02% QoQ
- FII holding
- 17.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Dr. Lal Pathlabs Acquisition
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Lal Pathlabs Employee Stock Options
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
- Value
- ₹1.42 Cr
Dr. Lal Pathlabs Acquisition Worth ₹168 Cr
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
- Value
- ₹168.0 Cr
Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
- Value
- ₹199.5 Cr